These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1884730)

  • 1. Debrisoquine oxidation polymorphism in a Tasmanian population.
    Veronese ME; McLean S
    Eur J Clin Pharmacol; 1991; 40(5):529-32. PubMed ID: 1884730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
    Wanwimolruk S; Patamasucon P; Lee EJ
    Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1988 May; 7(3):273-6. PubMed ID: 3391625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Debrisoquine oxidation in an Australian population.
    Peart GF; Boutagy J; Shenfield GM
    Br J Clin Pharmacol; 1986 May; 21(5):465-71. PubMed ID: 3718805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on the frequency distribution of debrisoquine hydroxylation deficiency in Chinese healthy Zang and Wei volunteers].
    Kuang TY; Liao XM; Wang KY; Zhang Y; Lou YQ
    Yao Xue Xue Bao; 1991; 26(4):250-4. PubMed ID: 1957669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
    Evans DA; Mahgoub A; Sloan TP; Idle JR; Smith RL
    J Med Genet; 1980 Apr; 17(2):102-5. PubMed ID: 7381862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metoprolol alpha-hydroxylation polymorphism in the San Bushmen of southern Africa.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1989 Jan; 8(1):39-43. PubMed ID: 2714809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
    Du YL; Lou YQ
    Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
    Broly F; Vandamme N; Libersa C; Lhermitte M
    Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population.
    Vincent-Viry M; Muller J; Fournier B; Galteau MM; Siest G
    Clin Chem; 1991 Mar; 37(3):327-32. PubMed ID: 2004438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
    McGourty JC; Silas JH; Lennard MS; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1985 Dec; 20(6):555-66. PubMed ID: 2868742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debrisoquine hydroxylation polymorphism in diabetic patients.
    Kallio J; Huupponen R; Viikari J
    Diabetes Res; 1990 Nov; 15(3):125-9. PubMed ID: 2132205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enantioselectivity of debrisoquine 4-hydroxylation in Brazilian Caucasian hypertensive patients phenotyped as extensive metabolizers.
    Cerqueira PM; Mateus FH; Cesarino EJ; Bonato PS; Lanchote VL
    J Chromatogr B Biomed Sci Appl; 2000 Dec; 749(2):153-61. PubMed ID: 11145052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype.
    Lennard MS; Tucker GT; Woods HF; Silas JH; Iyun AO
    Br J Clin Pharmacol; 1989 May; 27(5):613-6. PubMed ID: 2757883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.
    Dahl-Puustinen ML; Alm C; Bertilsson L; Christenson I; Ostman J; Thunberg E; Wikström I
    Br J Clin Pharmacol; 1990 Sep; 30(3):476-80. PubMed ID: 2121211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
    Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
    Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
    Wedlund PJ; Aslanian WS; McAllister CB; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1984 Dec; 36(6):773-80. PubMed ID: 6499356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
    Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
    Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphic debrisoquin metabolism in a Turkish population.
    Bozkurt A; Basci NE; Isimer A; Sayal A; Kayaalp SO
    Clin Pharmacol Ther; 1994 Apr; 55(4):399-401. PubMed ID: 8162666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.